Morgantown, WV, United States
Morgantown, WV, United States

Time filter

Source Type

NEW YORK, NY, November 04, 2016-- The West Virginia Mesothelioma Victims Center says, "There are a significant number-of mesothelioma lawyer advertisements on the Internet that make it sound like no lawsuit is needed or that there is such a thing as a federally sponsored mesothelioma claims center. There is one slight problem-these notions would be false as a lawsuit may be needed to get the best mesothelioma compensation and there is no federally sponsored claims center."As we would like to explain anytime at 800-714-0303-to get the very best mesothelioma compensation a lawsuit may be needed and a diagnosed person should have one of the nation's most skilled mesothelioma attorneys assisting a diagnosed person in West Virginia with their compensation claim-that might include a lawsuit and a trial. If you want the best mesothelioma compensation you will need the nation's most skilled mesothelioma attorneys assisting you." http://WestVirginia.MesotheliomaVictimsCenter.Com The types of people with mesothelioma in West Virginia the West Virginia Mesothelioma Victims Center specializes in helping include coal miners, steel mill workers, US Navy Veterans, power plant workers, manufacturing, or industrial workers, plumbers, electricians, welders, auto mechanics, machinists, or construction workers. In most instances these workers were exposed to asbestos in the 1950's, 1960's, 1970's, or 1980's.The Center says, "Please do not hire a lawyer to assist with a mesothelioma compensation claim in West Virginia if they have never done a trial involving asbestos exposure. If you hire someone like this you are probably shortchanging yourself as we would like to detail anytime at 800-714-0303." http://WestVirginia.MesotheliomaVictimsCenter.Com The West Virginia Mesothelioma Victims Center wants to emphasize their unsurpassed free services are available statewide to a diagnosed victim in any community in the Mountain State including Wheeling, Morgantown, Martinsburg, Charleston, Huntington, and Fairmont.The West Virginia Mesothelioma Victims Center is also incredibly focused on making certain a diagnosed victim in the Mountain State has the best treatment options. Two of the better options for diagnosed victims in West Virginia include the Mary Babb Randolph Cancer Center in Morgantown, or the University of Pittsburgh's Cancer Institute:* The Mary Babb Randolph Cancer Center Morgantown, West Virginia :http://www.wvucancer.org/.#sthash.lf6xcXiQ.dpuf* The University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania: http://upci.upmc.edu/ The average age for a diagnosed victim of mesothelioma is 72 years old. Frequently victims of mesothelioma are initially misdiagnosed with pneumonia. This year between 2500, and 3000 US citizens will be diagnosed with mesothelioma. Mesothelioma is attributable to exposure to asbestos.The states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer: http://www.nlm.nih.gov/medlineplus/mesothelioma.html


Lorusso P.M.,Barbara Ann Karmanos Cancer Institute | Krishnamurthi S.,Case Western Reserve University | Youssoufian H.,Ziopharm | Hall N.,Imclone Systems | And 6 more authors.
Investigational New Drugs | Year: 2014

Background IMC-18F1 (icrucumab), a human monoclonal antibody against vascular endothelial growth factor receptor-1 (VEGFR-1), potently inhibits ligand-dependent phosphorylation of VEGFR-1 and downstream signaling, making icrucumab an attractive candidate for antitumor activity. Objectives The primary objective was to determine the safety profile and maximum tolerated dose of icrucumab in patients with advanced solid tumors that were previously unresponsive to standard therapy or for which no standard therapy was available. Methods In this open-label, dose-escalation, Phase 1 study, patients received icrucumab intravenously weekly at 2, 3, 6, and 12 mg/kg (Cohorts 1-4), every other week (q2w) at 15 mg/kg (Cohort 5), or every third week at 20 mg/kg (Cohort 6). Patients received icrucumab until evidence of progressive disease or other withdrawal criteria were met. Results Twenty-six patients received icrucumab. The most common adverse events were fatigue, nausea, peripheral edema, anemia, dyspnea, and vomiting. No dose-limiting toxicities (DLTs) were observed in Cohorts 1-5. Two DLTs were observed in Cohort 6 (anemia and hyponatremia), and enrollment was stopped. No patient demonstrated an immunogenic response. Overall, icrucumab exhibited nonlinear pharmacokinetics at doses >6 mg/kg. Six patients (23.1 %) achieved stable disease with median duration of 11.1 weeks (range = 10.3-18.7 weeks); tumor types were thyroid, melanoma, colorectal (3 patients), and small-cell lung cancers. Conclusions Icrucumab was safely administered weekly at doses of 2-12 mg/kg and q2w at a dose of 15 mg/kg with no DLTs. Based on achievement of stable disease, icrucumab has potential for antitumor activity against advanced solid tumors. © 2013 Springer Science+Business Media New York.


Luo H.,Alderson Broaddus College | Jiang B.,West Virginia University | Li B.,West Virginia University | Li B.,Mary Babb Randolph Cancer Center | And 3 more authors.
International Journal of Nanomedicine | Year: 2012

Ovarian cancer is one of the leading causes of cancer death for women throughout the Western world. Kaempferol, a natural flavonoid, has shown promise in the chemoprevention of ovarian cancer. A common concern about using dietary supplements for chemoprevention is their bioavailability. Nanoparticles have shown promise in increasing the bioavailability of some chemicals. Here we developed five different types of nanoparticles incorporating kaempferol and tested their efficacy in the inhibition of viability of cancerous and normal ovarian cells. We found that positively charged nanoparticle formulations did not lead to a significant reduction in cancer cell viability, whereas nonionic polymeric nanoparticles resulted in enhanced reduction of cancer cell viability. Among the nonionic polymeric nanoparticles, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) nanoparticles incorporating kaempferol led to significant reduction in cell viability of both cancerous and normal cells. Poly(DL-lactic acid-co-glycolic acid) (PLGA) nanoparticles incorporating kaempferol resulted in enhanced reduction of cancer cell viability together with no significant reduction in cell viability of normal cells compared with kaempferol alone. Therefore, both PEO-PPO-PEO and PLGA nanoparticle formulations were effective in reducing cancer cell viability, while PLGA nanoparticles incorporating kaempferol had selective toxicity against cancer cells and normal cells. A PLGA nanoparticle formulation could be advantageous in the prevention and treatment of ovarian cancers. On the other hand, PEO-PPO-PEO nanoparticles incorporating kaempferol were more effective inhibitors of cancer cells, but they also significantly reduced the viability of normal cells. PEO-PPO-PEO nanoparticles incorporating kaempferol may be suitable as a cancer-targeting strategy, which could limit the effects of the nanoparticles on normal cells while retaining their potency against cancer cells. We have identified two nanoparticle formulations incorporating kaempferol that may lead to breakthroughs in cancer treatment. Both PEO-PPO-PEO and PLGA nanoparticle formulations had superior effects compared with kaempferol alone in reducing cancer cell viability. © 2012 Luo et al, publisher and licensee Dove Medical Press Ltd.


Trickett H.B.,West Virginia University | Cumpston A.,Mary Babb Randolph Cancer Center | Craig M.,WVU Healthcare
American Journal of Health-System Pharmacy | Year: 2012

Purpose. Sweet's syndrome (also known as acute febrile neutrophilic dermatosis) in two patients receiving azacitidine therapy is reported. Summary. The development of Sweet's syndrome in association with azacitidine use is rare (three published case reports since the drug's U.S. marketing approval in 2004), and the syndrome is not listed as a potential adverse reaction in the product packaging. In one of two cases of probable azacitidine-related Sweet's syndrome reported here, a 64-year-old man with myelodysplastic syndrome (MDS) developed a severe erythematous and nodular rash with peeling on his arms, legs, and face after receiving the drug (75 mg/m 2 subcutaneously daily) for three days; the second case involved a 67-year-old man with chronic myelomonocytic leukemia (CMML) who experienced a similar skin rash, as well as chills and an elevated body temperature, after five days of treatment with azacitidine. In both cases, the results of dermatologic or pathologic examination and skin biopsies were consistent with Sweet's syndrome. Perhaps the strongest evidence of a drug-induced etiology in these cases was the close temporal relationship between the initiation of azacitidine use and the development of Sweet's syndrome, with prompt symptom resolution after the discontinuation of azacitidine use and administration of appropriate corticosteroid therapy. Conclusion. Azacitidine was the apparent cause of Sweet's syndrome in a patient with MDS and another with CMML. Both responded well to corticosteroid therapy. After resolution of the reaction, decitabine was given to the first patient and azacitidine to the second, without complications. Copyright © 2012, American Society of Health-System Pharmacists, Inc. All rights reserved.


Lohcharoenkal W.,Mary Babb Randolph Cancer Center | Wang L.,U.S. National Institute for Occupational Safety and Health | Stueckle T.A.,U.S. National Institute for Occupational Safety and Health | Dinu C.Z.,West Virginia University | And 3 more authors.
ACS Nano | Year: 2013

Malignant mesothelioma is one of the most aggressive forms of cancer known. Recent studies have shown that carbon nanotubes (CNTs) are biopersistent and induce mesothelioma in animals, but the underlying mechanisms are not known. Here, we investigate the effect of long-term exposure to high aspect ratio CNTs on the aggressive behaviors of human pleural mesothelial cells, the primary cellular target of human lung mesothelioma. We show that chronic exposure (4 months) to single- and multiwalled CNTs induced proliferation, migration, and invasion of the cells similar to that observed in asbestos-exposed cells. An up-regulation of several key genes known to be important in cell invasion, notably matrix metalloproteinase-2 (MMP-2), was observed in the exposed mesothelial cells as determined by real-time PCR. Western blot and enzyme activity assays confirmed the increased expression and activity of MMP-2. Whole genome microarray analysis further indicated the importance of MMP-2 in the invasion gene signaling network of the exposed cells. Knockdown of MMP-2 in CNT and asbestos-exposed cells by shRNA-mediated gene silencing effectively inhibited the aggressive phenotypes. This study demonstrates CNT-induced cell invasion and indicates the role of MMP-2 in the process. © 2013 American Chemical Society.


Noore J.,West Virginia University | Noore A.,West Virginia University | Li B.,West Virginia University | Li B.,Mary Babb Randolph Cancer Center
Antimicrobial Agents and Chemotherapy | Year: 2013

The increasing resistance of bacteria to conventional antibiotics and the challenges posed by intracellular bacteria, which may be responsible for chronic and recurrent infections, have driven the need for advanced antimicrobial drugs for effective elimination of both extra- and intracellular pathogens. The purpose of this study was to determine the killing efficacy of cationic antimicrobial peptide LL-37 compared to conventional antibiotics against extra- and intracellular Staphylococcus aureus. Bacterial killing assays and an infection model of osteoblasts and S. aureus were studied to determine the bacterial killing efficacy of LL-37 and conventional antibiotics against extra- and intracellular S. aureus. We found that LL-37 was effective in killing extracellular S. aureus at nanomolar concentrations, while lactoferricin B was effective at micromolar concentrations and doxycycline and cefazolin at millimolar concentrations. LL-37 was surprisingly more effective in killing the clinical strain than in killing an ATCC strain of S. aureus. Moreover, LL-37 was superior to conventional antibiotics in eliminating intracellular S. aureus. The kinetic studies further revealed that LL-37 was fast in eliminating both extra- and intracellular S. aureus. Therefore, LL-37 was shown to be very potent and prompt in eliminating both extra- and intracellular S. aureus and was more effective in killing extra- and intracellular S. aureus than commonly used conventional antibiotics. LL-37 could potentially be used to treat chronic and recurrent infections due to its effectiveness in eliminating not only extracellular but also intracellular pathogens. Copyright © 2013, American Society for Microbiology.


Luo H.,Alderson Broaddus College | Li B.,West Virginia University | Li B.,Mary Babb Randolph Cancer Center | Li Z.,Alderson Broaddus College | And 3 more authors.
Anti-Cancer Drugs | Year: 2013

Ovarian cancer is the fifth leading cause of cancer deaths for women in America. With no known carcinogens or manageable risk factors, targeted prevention is currently unavailable. Angioprevention is a nonspecific strategy to limit the growth of solid tumors and is especially suitable for ovarian cancers. In search of angiopreventive agents, we examined chaetoglobosin K (ChK), a natural cytochalasan compound from the fungus Diplodia macrospora. We found that ChK significantly inhibits cell viability at concentrations as low as 0.5 μmol/l for A2780/CP70 ovarian cancer cells and 1.0 μmol/l for OVCAR-3 cells. ChK also significantly inhibits the secretion of key angiogenesis mediators, including Akt (which is also known as protein kinase B), hypoxia-inducible factor 1α (HIF-1α), and vascular epithelial growth factor (VEGF) by ovarian cancer cells. More importantly, ChK inhibits in-vitro and in-vivo angiogenesis induced by ovarian cancer cells and reduces the migratory capability of human umbilical vein endothelial cells. Through transfection of HIF-1α plasmids in luciferase assays, we found that ChK executes its VEGF inhibition by mediating the downregulation of HIF-1α. Furthermore, chromatin immunoprecipitation assays using the HIF-1α antibody revealed that ChK inhibits the interaction of HIF-1α with the VEGF promoter. Through transfection of Akt plasmids, we found that inhibition of HIF-1α by ChK occurs through downregulation of Akt. To our knowledge, this is the first report about the potential angioprevention of ChK. Our data suggest that this natural fungal bioactive compound effectively inhibits angiogenesis through downregulation of VEGF-binding HIF-1α and could be an effective agent for cancer treatment. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.


Li H.,West Virginia University | Li H.,University of Pittsburgh | Hamza T.,West Virginia University | Tidwell J.E.,West Virginia University | And 3 more authors.
Advanced Healthcare Materials | Year: 2013

Platelet-rich-plasma (PRP) has attracted great attention and has been increasingly used for a variety of clinical applications including orthopedic surgeries, periodontal and oral surgeries, maxillofacial surgeries, plastic surgeries, and sports medicine. However, very little is known about the antimicrobial activities of PRP. PRP is found to have antimicrobial properties both in vitro and in vivo. In vitro, the antimicrobial properties of PRP are bacterial-strain-specific and time-specific: PRP significantly (80-100 fold reduction in colony-forming units) inhibits the growth of methicillin-sensitive and methicillin-resistant Staphylococcus aureus, Group A streptococcus, and Neisseria gonorrhoeae within the first few hours but it has no significant antimicrobial properties against E. coli and Pseudomonas. The antimicrobial properties of PRP also depend on the concentration of thrombin. In vivo, an implant-associated spinal infection rabbit model is established and used to evaluate the antimicrobial and wound-healing properties of PRP. Compared to the infection controls, PRP treatment results in significant reduction in bacterial colonies in bone samples at all time points studied (i.e. 1, 2, and 3 weeks) and significant increase in mineralized tissues (thereby better bone healing) at postoperative weeks 2 and 3. PRP therefore may be a useful adjunct strategy against postoperative implant-associated infections. Platelet-rich-plasma (PRP) shows unique antimicrobial properties both in vitro and in vivo. An implant-associated spinal infection rabbit model shows that PRP treatment leads to a significant reduction in bacterial burdens together with a significant improvement in wound healing. PRP could be an advanced healthcare material against postoperative implant-associated infections. © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Hamza T.,West Virginia University | Li B.,West Virginia University | Li B.,Mary Babb Randolph Cancer Center
BMC Microbiology | Year: 2014

Background: Staphylococcus aureus (S. aureus) is one of the primary causes of bone infections which are often chronic and difficult to eradicate. Bacteria like S. aureus may survive upon internalization in cells and may be responsible for chronic and recurrent infections. In this study, we compared the responses of a phagocytic cell (i.e. macrophage) to a non-phagocytic cell (i.e. osteoblast) upon S. aureus internalization. Results: We found that upon internalization, S. aureus could survive for up to 5 and 7 days within macrophages and osteoblasts, respectively. Significantly more S. aureus was internalized in macrophages compared to osteoblasts and a significantly higher (100 fold) level of live intracellular S. aureus was detected in macrophages compared to osteoblasts. However, the percentage of S. aureus survival after infection was significantly lower in macrophages compared to osteoblasts at post-infection days 1-6. Interestingly, macrophages had relatively lower viability in shorter infection time periods (i.e. 0.5-4 h; significant at 2 h) but higher viability in longer infection time periods (i.e. 6-8 h; significant at 8 h) compared to osteoblasts. In addition, S. aureus infection led to significant changes in reactive oxygen species production in both macrophages and osteoblasts. Moreover, infected osteoblasts had significantly lower alkaline phosphatase activity at post-infection day 7 and infected macrophages had higher phagocytosis activity compared to non-infected cells. Conclusions: S. aureus was found to internalize and survive within osteoblasts and macrophages and led to differential responses between osteoblasts and macrophages. These findings may assist in evaluation of the pathogenesis of chronic and recurrent infections which may be related to the intracellular persistence of bacteria within host cells. © 2014 Hamza and Li; licensee BioMed Central Ltd.


Khimani F.,Mary Babb Randolph Cancer Center | Curley B.,Mary Babb Randolph Cancer Center | Almubarak M.,Mary Babb Randolph Cancer Center
Journal of Oncology Practice | Year: 2015

Objective: To investigate patients' knowledge and understanding of benign hematology and the potential psychological impact that is associated with referral to outpatient clinics. Methods: At Mary Babb Randolph Cancer Center, an anonymous and voluntary survey including 28 questions was designed on the basis of information obtained from a single focus group. A participatory pilot survey was performed with 10 patients followed by a full-scale survey from May until November 2013. Statistical software was used for analysis. Results: Among 98 patients who received the questionnaire, 37.6% were men, 62.4% women, 70.9% ≥ 40 years of age, 94.6% white, and 51.6% had some college education or above. Of the patients surveyed, 62.4% were surprised to find that their appointment was at a cancer center, and 36.6% received no explanation before their referral. A total of 61.3% did not know what benign hematology was, and only 61.2% knew that cancer physicians are also frequently trained to see patients with benign hematology conditions. Among the patients, 46.2% and 39.8% had an increase in anxiety and stress, respectively; 30.1% were afraid that they might have cancer; and 32.3% thought that the reason for their referral to the cancer center was for an evaluation for cancer. Knowledge was significantly better in women patients and patients who had been seen by an outside hematologist before or had been to a cancer center before. Conclusion: Referral to outpatient clinics in a cancer center for benign hematologic diseases seems to increase psychological stress and anxiety among patients, who may perceive that they are being referred for evaluation of a cancer diagnosis. Copyright © 2015 American Society of Clinical Oncology. All rights reserved.

Loading Mary Babb Randolph Cancer Center collaborators
Loading Mary Babb Randolph Cancer Center collaborators